ARCHIVES

DeVita’s “Radical” Statement – Resectability Rate Should Be The Cure Rate

This article is from The Cancer Letter archive.

Vol. 02 No. 40 | October 1, 1976

Download PDF Visit The Full Archive

Related Articles

Glaxo, Mass General Begin Phase III Trial Of Tykerb

December 29, 2006

President Accepts Rauscher Resignation

October 1, 1976

Regulatory Approvals: Gardasil 9 approved, which covers five additional HPV types

December 12, 2014

In Brief: Cancer Research Institute to Support AIDS Grants, With Maximum $70,000 Each; Deadline Is Oct. 1

July 15, 1983

Cvitkovic Responds To Story On March ODAC Meeting.

June 23, 2000

In Brief: Moon, Love, Head ASPO; $10 Million For Indiana Cancer Facility Included In Energy Dept. Budget

August 9, 1991